Drugs / Lucanthone

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy2 trials
Phase 2 NCT02014545 Comparator Jan 2016 → Nov 2017 metastatic malignant neoplasm in the brain, non-small cell lung carcinoma Wake Forest University Health Sciences Withdrawn No outcome recorded
Phase 2 NCT01587144 Comparator Jun 2012 → Apr 2013 glioblastoma Spectrum Pharmaceuticals, Inc Terminated No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Lucanthone ClinicalTrials.gov intervention name — accepted as the source's own label NCT01587144 ↗
1

NCT02014545 ↗

Known as 79 T61 ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Lucanthone hcl ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as LUCANTHONE HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Lucantona ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Miracil d ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Miracol ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as MS-752 ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Nilodin ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as NSC-14574 ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as RP-3735 ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Known as Tixantone ChEMBL registry synonym — accepted as the source's own label CHEMBL279014 ↗
Modality Small molecule — CHEMBL279014 ↗
Route Oral “Lucanthone will be given as an oral” NCT01587144 ↗